Literature DB >> 10746668

Expressions of cell-cycle regulatory gene products in conventional gastric adenomas: possible immunohistochemical markers of malignant transformation.

M Oya1, T Yao, M Tsuneyoshi.   

Abstract

In 54 lesions of gastric adenomas consisting of 31 low-grade adenomas (LGAs) and 23 high-grade adenomas (HGAs), 28 intramucosal carcinomas (IMCs), and 23 carcinomas invading the submucosa (SMCs), the expression of cell-cycle regulatory gene products (p53, p21/waf1, p27/kip1, and Ki-67) was studied using immunohistochemical techniques. Several lesions were also analyzed by the fluorescence in situ hybridization method. The overexpression of p53 was found in no LGAs and in 9% of HGAs, whereas a considerable number of cases showed an overexpression in IMCs (39%) and SMCs (43%). A reduced expression of p21/waf1 was present in only 4% of HGAs. Superficial eccentric positivity was present in all LGAs and 74% of HGAs, whereas it was present in 46% of IMCs and 4% of SMCs. P53-positive and p21/waf1-negative lesions, which were supposed to have a mutated p53 gene, were observed in no LGAs, in 4% of HGAs, in 11% of IMCs, and in 26% of SMCs. The expression of cyclin E was more frequently present in carcinomas than in adenomas. However, no high expression of cyclin E was observed among the adenomas. A reduced expression of p27/kip1 was encountered more frequently in carcinoma than adenoma. By a semiquantitative evaluation comparing adenoma and carcinoma in the same stomach, the increased degrees of both p21/waf1 and cyclin E were highlighted. A chromosome gain was detected among 7% of the adenomas and 85% of the carcinomas. In conclusion, the expressions of p53, p21/waf1, p27/kip1, and cyclin E were considered to be of great value for estimating the dysplastic progression of gastric adenomas. Especially, various aspects of protein expression, including its distribution and semiquantitative evaluation of positive cells, and a combined analysis with several proteins, may thus be useful as possible markers of dysplastic evolution in gastric adenomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10746668     DOI: 10.1016/s0046-8177(00)80239-7

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

1.  Extremely well-differentiated adenocarcinoma of the stomach: clinicopathological and immunohistochemical features.

Authors:  Takashi Yao; Takashi Utsunomiya; Masafumi Oya; Kenichi Nishiyama; Masazumi Tsuneyoshi
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

2.  Gastric epithelial proliferation and p53 and p21 expression in a general population sample: relations to age, sex, and mucosal changes associated with H. pylori infection.

Authors:  Fredrik Petersson; Kurt Borch; Lennart E Franzén
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

3.  Expression of p21(WAF1) and p53 and polymorphism of p21(WAF1) gene in gastric carcinoma.

Authors:  Hai-Long Xie; Qi Su; Xiu-Sheng He; Xiao-Qiu Liang; Jian-Guo Zhou; Yin Song; Yi-Qin Li
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

4.  Down-regulation of CCNE1 expression suppresses cell proliferation and sensitizes gastric carcinoma cells to Cisplatin.

Authors:  Chao Zhang; Qiang Zhu; Jianzhong Gu; Shan Chen; Qian Li; Liping Ying
Journal:  Biosci Rep       Date:  2019-06-04       Impact factor: 3.840

5.  Diagnostic value of negative enrichment and immune fluorescence in situ hybridization for intraperitoneal free cancer cells of gastric cancer.

Authors:  Anqiang Wang; Zhongwu Li; Qian Wang; Yali Bai; Xin Ji; Tao Fu; Ke Ji; Yanwen Xue; Tingxu Han; Xiaojiang Wu; Ji Zhang; Yingjie Yang; Guobin Xu; Zhaode Bu; Jiafu Ji
Journal:  Chin J Cancer Res       Date:  2019-12       Impact factor: 5.087

6.  HER2-positive double primary tumor of gastric and breast cancer occur synchronously in a patient: A case report.

Authors:  Quchang Ouyang; Can Tian; Jianxiang Gao; Jin Huang; Hua Fu; Jinsong He; Jianbo Yang
Journal:  Mol Clin Oncol       Date:  2016-03-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.